ISSCR News
The ISSCR Files Amicus Brief Supporting FDA’s Authority to Regulate Unproven Stem Cell-Based Interventions
The International Society for Stem Cell Research (ISSCR) filed an amicus curiae brief today to support the U.S. government’s appeal in U.S. v. California Stem Cell Treatment Center, Inc., a case that ruled the Food and Drug Administration (FDA) cannot regulate dangerous unproven stem cell-based interventions.
The ISSCR Releases Global Standards to Enhance Rigor and Reproducibility of Stem Cell Research
The International Society for Stem Cell Research (ISSCR) today released the ISSCR Standards for Human Stem Cell Use in Research, an international collaboration aimed at enhancing rigor in preclinical research and ultimately strengthening the pipeline of therapies for patients.
Stem Cell Reports Marks 10 Years of Advancing Stem Cell Science
In June, International Society for Stem Cell Research (ISSCR) society journal, Stem Cell Reports, officially celebrates 10 years of publishing science that is moving the field of stem cell research forward.
In the inaugural issue of Stem Cell Reports published in June 2013, the editorial board shared the mission of the new journal – to deliver significant, well-documented findings to the stem cell research community in a timely manner. This foundation for the new journal, which started as a “leap of faith,” remains true today.
Chen Institute Partners with ISSCR to Establish Fellowship for Stem Cell Reports Early Career Editorial Board
The International Society for Stem Cell Research (ISSCR) is delighted to announce a partnership with the Tianqiao and Chrissy Chen Institute, establishing a fellowship program to support members of the Stem Cell Reports Early Career Editorial Board (ECEB). The program facilitates attendance at the ISSCR Annual Meeting, mentoring opportunities, and the development of scientific programs that will cultivate and deepen leadership skills.
Pluripotent Stem Cells Take Over From Blood Stem Cells for Future Transplant Therapies
New research published in Stem Cell Reports from Jinyong Wang and colleagues with the Chinese Academy of Sciences and Guangzhou Medical University has now optimized a combination of proteins, so-called transcription factors, which when introduced in mouse PSCs convert them to HSPCs in the dish. When transplanted into mice with impaired HSPCs, the PSC-derived cells generated all types of white blood cells over a period of 6 months. Importantly, the transplanted HSPCs did not give rise to tumors or leukemias in the receiving mice.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .